Zelpultide alfa is under clinical development by Airway Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zelpultide alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zelpultide alfa overview
AT-100 is under development for the treatment of bronchopulmonary dysplasia (BPD), influenza, respiratory syncytial virus (RSV), coronavirus disease 2019 (COVID-19), cystic fibrosis, other respiratory diseases and other inflammatory diseases. It is administered through intratracheal route. It is a recombinant human surfactant protein D (rhSP-D). SP-D is required for the normal structure and function of lung surfactant. It is a protein replacement therapy.
Airway Therapeutics overview
Airway Therapeutics is a biotechnology company. It develops therapeutics and biologics for life-threatening respiratory and inflammatory diseases. The company’s product pipeline AT-100 is a novel recombinant human protein rhSP-D – an engineered version of an endogenous protein – that reduces inflammation and infection while modulating the immune response to break the cycle of injury and inflammation. Its products are also used to treat influenzas, respiratory syncytial virus, COVID-19, and other respiratory, non-respiratory and anti-inflammatory diseases. Airway Therapeutics is headquartered in Marietta, Georgia, the US.
For a complete picture of Zelpultide alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
